GlassScriptPhysician profile
Monika Mishra
NPI 1841585437
$3,876.65
in general payments reported to CMS, 2019-2025
19 companies · $67.16 in 2025
The $67.16 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $18.35 · 2022: $538 · 2023: $1,766 · 2024: $766 · 2025: $67.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,598.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $955.19 | 2022-2025 | |
| Livanova USA, INC. | $618.25 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $438.41 | 2019-2024 | |
| Ucb, INC. | $395.81 | 2019-2024 | Briviact, Nayzilam |
| Pfizer INC. | $304.68 | 2023-2024 | |
| Boston Scientific Corporation | $298.05 | 2023-2024 | Vercise |
| Sk Life Science, INC. | $275.10 | 2022-2023 | |
| Lilly USA, LLC | $139.69 | 2022-2024 | Emgality, Reyvow |
| Lundbeck LLC | $94.39 | 2023-2024 | Rexulti |
| Argenx US, INC. | $79.46 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $57.83 | 2022-2023 | Rytary |
| Insightec,INC | $43.85 | 2023-2025 | Exablate |
| Amgen INC. | $42.00 | 2023 | Aimovig |
| Acadia Pharmaceuticals INC | $39.47 | 2023 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $27.96 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $22.93 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $19.37 | 2023 | Austedo |
| Sunovion Pharmaceuticals INC. | $17.21 | 2022 | |
| Sumitomo Pharma America, INC. | $7.00 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monika Mishra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.